Nuveen LLC acquired a new stake in shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 56,846 shares of the company's stock, valued at approximately $915,000. Nuveen LLC owned approximately 0.08% of Pulse Biosciences at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in the company. Bank of America Corp DE grew its stake in shares of Pulse Biosciences by 0.4% in the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after buying an additional 2,884 shares during the period. Westside Investment Management Inc. grew its stake in shares of Pulse Biosciences by 5.5% in the 1st quarter. Westside Investment Management Inc. now owns 58,155 shares of the company's stock valued at $936,000 after buying an additional 3,034 shares during the period. Pandora Wealth Inc. purchased a new stake in shares of Pulse Biosciences in the 1st quarter valued at approximately $828,000. Panoramic Capital LLC purchased a new stake in shares of Pulse Biosciences in the 4th quarter valued at approximately $846,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Pulse Biosciences by 14.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,308 shares of the company's stock valued at $667,000 after buying an additional 4,773 shares during the period. Hedge funds and other institutional investors own 76.95% of the company's stock.
Analyst Ratings Changes
Separately, Oppenheimer initiated coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They issued an "outperform" rating and a $22.00 price target for the company. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $22.00.
Check Out Our Latest Analysis on PLSE
Insider Activity at Pulse Biosciences
In other news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $16.40, for a total value of $246,000.00. Following the transaction, the chief technology officer directly owned 137,872 shares in the company, valued at approximately $2,261,100.80. This represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 74.60% of the company's stock.
Pulse Biosciences Price Performance
Shares of PLSE stock traded down $0.06 during trading hours on Friday, hitting $15.11. The company had a trading volume of 71,669 shares, compared to its average volume of 153,747. The company's fifty day moving average is $15.50 and its 200 day moving average is $16.31. Pulse Biosciences, Inc has a fifty-two week low of $13.77 and a fifty-two week high of $25.00. The stock has a market capitalization of $1.02 billion, a PE ratio of -14.39 and a beta of 1.68.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02).
Pulse Biosciences Company Profile
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Recommended Stories
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
